NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BMRN

Biomarin Pharmaceutical Inc

Jul 01 • 04:00PM ET

56.19

Dollar change +1.22
Percentage change 2.22	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX SRPT NBIX ALNY BLUE IONS RARE EXEL PRTA

| Held by: VTI IJH VB VXF VBK XBI MDY IBB IJJ SPMD

Scroll to Statements

Index	-	P/E	20.85	EPS (ttm)	2.69	Insider Own	1.42%	Shs Outstand	191.76M	Perf Week	2.74%
Market Cap	10.78B	Forward P/E	13.44	EPS next Y	4.18	Insider Trans	-0.43%	Shs Float	189.06M	Perf Month	-3.24%
Enterprise Value	10.11B	PEG	0.63	EPS next Q	0.83	Inst Own	98.01%	Short Float	2.34%	Perf Quarter	-20.51%
Income	523.88M	P/S	3.69	EPS this Y	57.82%	Inst Trans	0.96%	Short Ratio	2.08	Perf Half Y	-16.16%
Sales	2.92B	P/B	1.86	EPS next Y	19.85%	ROA	7.47%	Short Interest	4.42M	Perf YTD	-14.51%
Book/sh	30.21	P/C	8.47	EPS next 5Y	33.31%	ROE	9.64%	52W High	94.85 -40.76%	Perf Year	-32.71%
Cash/sh	6.63	P/FCF	17.26	EPS past 3/5Y	- -	ROIC	8.20%	52W Low	52.93 6.16%	Perf 3Y	-35.30%
Dividend Est.	-	EV/EBITDA	14.09	Sales past 3/5Y	15.43% 10.98%	Gross Margin	78.25%	Volatility	2.29% 2.51%	Perf 5Y	-53.42%
Dividend TTM	-	EV/Sales	3.46	EPS Y/Y TTM	152.10%	Oper. Margin	21.44%	ATR (14)	1.46	Perf 10Y	-59.86%
Dividend Ex-Date	-	Quick Ratio	3.49	Sales Y/Y TTM	17.99%	Profit Margin	17.93%	RSI (14)	48.66	Recom	1.52
Dividend Gr. 3/5Y	- -	Current Ratio	5.52	EPS Q/Q	108.02%	SMA20	0.82%	Beta	0.17	Target Price	96.81
Payout	0.00%	Debt/Eq	0.11	Sales Q/Q	12.72%	SMA50	-3.71%	Rel Volume	1.34	Prev Close	54.97
Employees	3040	LT Debt/Eq	0.10	Earnings	May 01 AMC	SMA200	-13.37%	Avg Volume	2.13M	Price	56.19
IPO	Jul 23, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	39.21% 0.88%	Trades		Volume	2,840,949	Change	2.22%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform	$98
Nov-15-24	Initiated	Wolfe Research	Outperform	$95
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform	$79
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform	$94 → $110
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral	$104 → $72
May-14-24	Initiated	Evercore ISI	Outperform	$113
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102
Jun-14-23	Resumed	Credit Suisse	Outperform	$120
Mar-21-23	Initiated	Bernstein	Underperform	$81
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral	$116
Jan-30-23	Initiated	BMO Capital Markets	Market Perform	$107
Jan-18-23	Initiated	Canaccord Genuity	Hold	$119
Oct-31-22	Upgrade	Oppenheimer	Perform → Outperform	$92 → $110

Show Previous Ratings

Today 08:45AM	BioMarin Announces Completion of Acquisition of Inozyme (PR Newswire)
Jun-28-25 04:16AM	BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A (Insider Monkey)
Jun-27-25 10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Jun-26-25 04:19AM	The Top 5 Analyst Questions From BioMarin Pharmaceutical's Q1 Earnings Call (StockStory)
09:45AM	Loading…
Jun-25-25 09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Jun-24-25 09:00AM	BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress (PR Newswire)
Jun-23-25 01:36AM	Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating (Insider Monkey)
12:01AM	2 Reasons to Watch BMRN and 1 to Stay Cautious (StockStory)
Jun-20-25 05:00PM	Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders (GlobeNewswire)
Jun-15-25 05:26AM	Jim Cramer on BioMarin: "I Don't Think It Works Now" (Insider Monkey)
Jun-11-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jun-09-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jun-05-25 03:06AM	Here Are All 6 Stocks I've Bought Through 5 Months of 2025 (Motley Fool)
May-28-25 11:40AM	Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock? (Zacks)
09:40AM	Loading…
May-26-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
May-22-25 12:35PM	Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More (Zacks)
09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-19-25 09:06AM	BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz (Zacks)
04:22AM	BioMarin agrees to acquire Inozyme for $270m (Pharmaceutical Technology)
May-18-25 08:17AM	BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition (Insider Monkey)
May-17-25 01:30PM	Leerink bullish on BioMarin following Inozyme deal, expects additional BD (TipRanks)
May-16-25 09:37AM	How BioMarin's $270 Million Takeover Led This Dollar Stock To A Triple-Digit Gain (Investor's Business Daily)
09:37AM	BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover (Investor's Business Daily)
08:26AM	BioMarin to buy rare disease drugmaker Inozyme for $270M (BioPharma Dive)
07:30AM	BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma (PR Newswire)
06:34AM	BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress (StockStory)
May-14-25 07:48AM	BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying (Insider Monkey)
May-12-25 09:05AM	BioMarin Presents New Data for VOXZOGO (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings (PR Newswire)
09:40AM	Loading…
May-09-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
04:41AM	BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer's Stock Picks with Huge Upside Potential (Insider Monkey)
12:37AM	1 Healthcare Stock with Competitive Advantages and 2 to Brush Off (StockStory)
May-07-25 04:11PM	BioMarin Pharmaceutical Inc. (BMRN): Among Stocks That Will Make You Rich In 3 Years (Insider Monkey)
May-06-25 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
May-05-25 09:50AM	Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term (Zacks)
May-02-25 05:57PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
01:23PM	BioMarin's First-Quarter Earnings & Sales Beat Estimates (Zacks)
08:13AM	Q1 2025 BioMarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Biomarin Pharmaceutical Inc (BMRN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-01-25 07:30PM	BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:25PM	BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:15PM	BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates (Zacks)
04:17PM	BioMarin: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance (PR Newswire)
Apr-29-25 11:38AM	BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-27-25 01:13PM	2 Cash-Producing Stocks with Exciting Potential and 1 to Question (StockStory)
Apr-23-25 08:47PM	BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
08:44AM	Implied Volatility Surging for BioMarin Stock Options (Zacks)
Apr-21-25 10:16AM	Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store? (Zacks)
Apr-18-25 09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Apr-17-25 10:00AM	Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:00AM	BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET (PR Newswire)
Apr-16-25 10:00AM	BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
09:53AM	Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last? (Zacks)
Apr-11-25 03:06AM	6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility (Motley Fool)
Apr-10-25 12:10PM	Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? (Zacks) -5.23%
08:17AM	Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength? (Zacks)
02:37AM	Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Apr-09-25 03:00PM	Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On (Zacks) +6.33%
Apr-08-25 09:56AM	Viatris to Pay $335 Million for Settlement of Opioid-Related Claims (Zacks) -5.53%
Apr-07-25 01:22PM	5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 (Zacks)
12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) (Zacks)
12:00PM	What Makes BioMarin (BMRN) a New Buy Stock (Zacks)
11:40AM	BMRN vs. CSLLY: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Apr-03-25 03:37PM	BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion (Seeking Alpha)
10:14AM	BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study (Zacks)
04:54AM	BioMarins trial for phenylketonuria therapy meets primary efficacy endpoint (Clinical Trials Arena)
Apr-02-25 03:06PM	BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients (Benzinga)
09:48AM	Is BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now? (Insider Monkey)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
09:00AM	BioMarin Announces Positive Pivotal Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria (PR Newswire)
Mar-28-25 09:50AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock (Zacks)
Mar-27-25 10:10AM	Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
05:06AM	5 Historically Cheap Growth Stocks to Buy With Confidence in the Wake of the Nasdaq Correction (Motley Fool)
Mar-26-25 05:11AM	2 Reasons to Like BMRN (and 1 Not So Much) (StockStory)
Mar-25-25 09:18PM	Is BioMarin Pharmaceutical Inc. (BMRN) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
Mar-21-25 11:30AM	BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? (Zacks)
10:10AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
05:05AM	Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) (StockStory)
Mar-20-25 03:25PM	BioMarin Pharmaceutical (BMRN): Among Paul Singer's Latest Portfolio's Top Stock Picks (InsiderMonkey)
09:00AM	BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting (PR Newswire)
Mar-19-25 05:05AM	A Look Back at Therapeutics Stocks Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack (StockStory)
Mar-18-25 05:55AM	Is BioMarin Pharmaceutical (BMRN) the Best Biotech Stock According to Billionaires? (Insider Monkey)
Mar-17-25 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Mar-12-25 12:45PM	Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
09:55AM	Wall Street Analysts Believe BioMarin (BMRN) Could Rally 36.57%: Here's is How to Trade (Zacks)
09:50AM	Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term (Zacks)
Mar-11-25 09:01AM	1 Healthcare Stock to Target This Week and 2 to Turn Down (StockStory)
05:03AM	Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks (StockStory)
Mar-05-25 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Mar-04-25 04:03AM	Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 (StockStory)
Feb-28-25 09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Feb-25-25 09:00AM	BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA (PR Newswire)
08:03AM	Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
08:03AM	What To Expect From United Therapeuticss (UTHR) Q4 Earnings (StockStory)
Feb-24-25 04:05PM	BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors (PR Newswire)
12:45PM	BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why (Zacks)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkhart Erin	GVP, Chief Accounting Officer	May 20 '25	Sale	59.31	1,786	105,928	14,173	May 20 05:58 PM
Burkhart Erin	Officer	May 20 '25	Proposed Sale	59.31	1,786	105,928		May 20 09:58 AM
Hubbard Cristin	EVP, Chief Commercial Officer	May 02 '25	Sale	64.92	273	17,723	32,700	May 06 05:07 PM
Hubbard Cristin	Officer	May 02 '25	Proposed Sale	64.92	273	17,723		May 02 10:05 AM
Burkhart Erin	GVP, Chief Accounting Officer	Mar 19 '25	Sale	71.52	1,295	92,618	16,955	Mar 20 07:38 PM
Burkhart Erin	Officer	Mar 19 '25	Proposed Sale	71.52	1,295	92,618		Mar 19 09:36 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Mar 06 '25	Sale	71.28	7,034	501,355	87,655	Mar 07 04:06 PM
Guyer Charles Greg	Officer	Mar 06 '25	Proposed Sale	71.28	7,034	501,359		Mar 06 04:05 PM
Burkhart Erin	GVP, Chief Accounting Officer	Feb 24 '25	Sale	68.38	1,344	91,903	13,105	Feb 25 08:21 PM
Burkhart Erin	Officer	Feb 24 '25	Proposed Sale	68.38	1,344	91,903		Feb 24 10:26 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Nov 12 '24	Sale	66.37	5,278	350,324	68,909	Nov 14 02:44 PM
Guyer Charles Greg	Officer	Nov 12 '24	Proposed Sale	66.37	5,278	350,324		Nov 12 02:27 PM
Burkhart Erin	GVP, Chief Accounting Officer	Aug 13 '24	Sale	90.00	714	64,260	14,449	Aug 15 03:57 PM
Burkhart Erin	Officer	Aug 13 '24	Proposed Sale	90.00	714	64,260		Aug 13 11:48 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMRN

Biomarin Pharmaceutical Inc

Upgrade your FINVIZ experience